Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Gattermann

Showing results (111-120 of 158) with videos related to

Pageof 16
Sort By:
Scientific Reports|April 8, 2025
The role of genetic testing in accurate diagnosis of X-linked sideroblastic anemia: novel ALAS2 mutations and the impact of X-chromosome inactivationDaniel Jové-Solavera, Marta Rámila, Xènia Ferrer-Cortés, et al.
Oncogene|April 5, 2005
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemiaRalf Kronenwett, Ulf Butterweck, Ulrich Steidl, et al.
Journal of Cancer Research and Clinical Oncology|April 9, 2026
High serum ferritin is associated with genetic instability in myelodysplastic neoplasmsChristina Ganster, Hannes Treiber, Gina Westhofen, et al.
International Journal of Hematology|January 20, 2009
Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndromeWolf C Prall, Akos Czibere, Franck Grall, et al.
Leukemia Research|May 14, 2021
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral centerKathrin Nachtkamp, Josefine Stark, Andrea Kündgen, et al.
British Journal of Haematology|February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-CPierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Blood|July 20, 2007
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromesAzim Mohamedali, Joop Gäken, Natalie A Twine, et al.
Blood|December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsJeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Experimental Hematology|November 9, 2002
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioningGuido Kobbe, Peter Schneider, Manuel Aivado, et al.
Oncotarget|July 3, 2018
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literatureAndrea Kuendgen, Catharina Müller-Thomas, Michael Lauseker, et al.
Pageof 16

Showing results (111-120 of 158) with videos related to

Sort By:
Pageof 16
Scientific Reports|April 8, 2025
The role of genetic testing in accurate diagnosis of X-linked sideroblastic anemia: novel ALAS2 mutations and the impact of X-chromosome inactivationDaniel Jové-Solavera, Marta Rámila, Xènia Ferrer-Cortés, et al.
Oncogene|April 5, 2005
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemiaRalf Kronenwett, Ulf Butterweck, Ulrich Steidl, et al.
Journal of Cancer Research and Clinical Oncology|April 9, 2026
High serum ferritin is associated with genetic instability in myelodysplastic neoplasmsChristina Ganster, Hannes Treiber, Gina Westhofen, et al.
International Journal of Hematology|January 20, 2009
Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndromeWolf C Prall, Akos Czibere, Franck Grall, et al.
Leukemia Research|May 14, 2021
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral centerKathrin Nachtkamp, Josefine Stark, Andrea Kündgen, et al.
British Journal of Haematology|February 9, 2010
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-CPierre Fenaux, Norbert Gattermann, John F Seymour, et al.
Blood|July 20, 2007
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromesAzim Mohamedali, Joop Gäken, Natalie A Twine, et al.
Blood|December 17, 2008
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsJeffrey W Tyner, Heidi Erickson, Michael W N Deininger, et al.
Experimental Hematology|November 9, 2002
Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioningGuido Kobbe, Peter Schneider, Manuel Aivado, et al.
Oncotarget|July 3, 2018
Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literatureAndrea Kuendgen, Catharina Müller-Thomas, Michael Lauseker, et al.
Pageof 16